An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 09 Aug 2017 According to a Medicenna Therapeutics media release, the company has safely treated 10 patients in this trial. Patient accrual at five new clinical sites is expected soon.
- 09 Jun 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
- 09 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Nov 2018.